Monographie - Mycophenolate mofetil

Última actualización :
19/11/2024

Mycophenolate mofetil

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Cellcept	Alemania, Australia, Austria, Canadá, Colombia, Dinamarca, España, Estados Unidos de América, Finlandia, Francia, Gran Bretaña, Grecia, Hungría, Irlanda, Italia, Japón, Luxemburgo, México, Noruega, Nueva Zelanda, Países Bajos, Polonia, Portugal, Suecia, Suiza
Micofenolato de mofetilo	España
Mycophenolate mofetil	Alemania, Bélgica, Gran Bretaña

Bibliografía : Mycophenolate mofetil

	Tipo	Publicación
1981	periódico	Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C. Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags. Am J Health-Syst Pharm 2002 ; 59: 2434-2439.
1982	periódico	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108	periódico	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2192	periódico	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247	periódico	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3728	periódico	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3828	póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4299	periódico	Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M. Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device. Biomed Chromatogr 2019 ; 33, 7: e4529.
4528	periódico	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4698	periódico	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022

Mentions Légales